ReviewAnnals of joint2025
Considerations in revision of anterior cruciate ligament reconstruction in the high-level athlete.
Review in Annals of joint, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Anterior cruciate ligament (ACL) graft failure following ACL reconstruction (ACLR) remains a persistent challenge, especially in the high-level athlete. This review aims to provide a comprehensive overview of the key considerations in revision ACLR, with a particular focus on the high-level athlete. ACL graft failure is multifactorial in origin, with the most common technical error being femoral tunnel malposition. Preoperative evaluation should include a thorough history, physical examination, and advanced imaging such as magnetic resonance imaging and three-dimensional (3D) computed tomography (CT) to assess tunnel position, osteolysis, and associated intra-articular pathology. Concomitant injuries, including meniscal tears and collateral ligament insufficiencies, must be identified and appropriately addressed during revision surgery. Surgical planning must consider prior ACL graft choice, ACL tunnel position, and the potential need for a staged procedure. ACL graft selection should be individualized, though autografts, particularly bone-patellar tendon-bone (BPTB) and quadriceps tendon (QT), are preferred over hamstring tendon (HT) or allograft due to superior outcomes. The decision to perform a single-stage versus two-stage revision is influenced by tunnel placement and tunnel lysis, with a CT scan aiding in preoperative planning. Adjunctive procedures such as a lateral extra-articular tenodesis (LET) or anterolateral ligament (ALL) reconstruction may be considered when certain high-risk characteristics are present, such as young age, knee hyperextension >5 degrees, high-grade pivot shift, multiple revisions, and increased posterior tibial slope (PTS) not meeting criteria for slope-correcting osteotomy. Additionally, slope-reducing or coronal alignment-correcting osteotomies may be necessary in select cases to optimize knee biomechanics and prevent further failure, but literature regarding return to high-level sport following these procedures is limited. Return to sport (RTS) following revision ACLR should be approached as a continuum, incorporating strength, neuromuscular control, and psychological readiness, with emphasis on individualized, criteria-based protocols. Delaying RTS to at least 9 months postoperatively has been associated with reduced ACL graft failure risk. Overall, revision ACLR in the high-level athlete is a complex and nuanced procedure that requires a meticulous, multifactorial approach. By tailoring surgical strategies and postoperative rehabilitation, surgeons can optimize outcomes and facilitate a safe return to competitive sport.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.